• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetes Metab Syndr . The prognostic value of elevated creatine kinase to predict poor outcome in patients with COVID-19 - A systematic review and

tetano

Editor, Senior Moderator
Diabetes Metab Syndr


. 2021 Feb 11;15(2):529-534.
doi: 10.1016/j.dsx.2021.02.012. Online ahead of print.
The prognostic value of elevated creatine kinase to predict poor outcome in patients with COVID-19 - A systematic review and meta-analysis


Mohammad Rizki Akbar[SUP] 1 [/SUP], Raymond Pranata[SUP] 2 [/SUP], Arief Wibowo[SUP] 3 [/SUP], Michael Anthonius Lim[SUP] 4 [/SUP], Teddy Arnold Sihite[SUP] 5 [/SUP], Januar Wibawa Martha[SUP] 6 [/SUP]



Affiliations
Free PMC article

Abstract

Background and aims: Creatine kinase (CK), a marker of muscle damage, is potentially associated with a more severe COVID-19. In this systematic review and meta-analysis, we aim to evaluate the association between the elevated CK and severity and mortality in COVID-19.
Methods: We performed a systematic literature search on PubMed, Scopus, and Embase up until January 26, 2020. The main outcome was poor outcome, a composite of mortality and severe COVID-19.
Results: There are 2471 patients from 14 studies included in this systematic review and meta-analysis. The incidence of elevated CK in this pooled analysis was 17% (11%, 22%) and the incidence of poor outcome in this pooled analysis was 27% (19%, 34%). Elevated CK was associated with poor outcome in patients with COVID-19 (OR 3.01 [2.21, 4.10], p < 0.001; I[SUP]2[/SUP]: 10.2%). The effect estimate did not vary with age (p = 0.610), male (p = 0.449), hypertension (p = 0.490), and diabetes (p = 0.457). Elevated CK has a sensitivity of 0.24 (0.17, 0.32), specificity of 0.91 (0.86, 0.94), PLR of 2.6 (1.9, 3.7), NLR of 0.84 (0.78, 0.90), DOR of 3 (2, 5), and AUC of 0.62 (0.57, 0.66) for predicting poor outcome in patients with COVID-19. In this pooled analysis, elevated CK confers to a 49% probability for poor outcome and a non-elevated CK confers to a 24% probability. Subgroup analysis and univariate meta-regression indicates that the sensitivity and specificity does not vary with age, male, hypertension, and diabetes.
Conclusion: Elevated CK was associated with increased mortality and severity in patients with COVID-19.
Prospero: CRD42021233435.

Keywords: Coronavirus; Creatine kinase; Mortality; Myopathy; Severity.
 
Back
Top Bottom